Data extraction The generic and brand names of GLP-1 RAs approved by the FDA were used to identify adverse events of GLP-1 RAs in the DRUG files, including exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), dulaglutide (TRULICITY), lixisenatide (ADLYXIN, SOLIQUA), and semaglutide (OZEMPIC, RYBELSUS, WEGOVY)
These DNA nanostructures may include tiny functional molecules and/or ligands for bioimaging or site-specific attachment (121)
In particular, superimposed thrombosis is responsible for the most devastating consequences of AS, such as heart attacks and strokes
However, visible weight loss may not be apparent just yet as your body gradually adjusts to the new metabolic changes